Deep Insight into the Role of MIF in Spondyloarthritis.

IF 5.7 2区医学 Q1 RHEUMATOLOGY Current Rheumatology Reports Pub Date : 2022-09-01 Epub Date: 2022-07-09 DOI:10.1007/s11926-022-01081-7

Brian Wu, Akihiro Nakamura

{"title":"Deep Insight into the Role of MIF in Spondyloarthritis.","authors":"Brian Wu, Akihiro Nakamura","doi":"10.1007/s11926-022-01081-7","DOIUrl":null,"url":null,"abstract":"Purpose of review: Pathological roles of macrophage migration inhibitory factor (MIF) have recently been demonstrated in spondyloarthritis (SpA) preclinical models, identifying MIF as a new treatment target for SpA. However, the specific contribution of MIF and therapeutic potential of MIF-targeted therapies to various tissue types affected by SpA are not well delineated.Recent findings: MIF and its cognate receptor CD74 are extensively involved in the pathogenesis of SpA including inflammation in the spine, joint, eyes, skin, and gut. The majority of the current evidence has consistently shown that MIF drives the inflammation in these distinct anatomical sites. In preclinical models, genetic deletion or blockade of MIF reduces the severity of inflammation. Although MIF is generally an upstream cytokine which regulates downstream effector cytokines, MIF also intensifies type 3 immunity by promoting helper T 17 (Th17) plasticity. MIF- or CD74-targeted therapies have also reported to be well tolerated in clinical trials for other diseases. Recent findings suggest that MIF-CD74 axis is a new therapeutic target for SpA to improve various clinical features. Clinical trials for MIF- or CD74-targeted therapies for SpA patients are warranted.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"24 9","pages":"269-278"},"PeriodicalIF":5.7000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Rheumatology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11926-022-01081-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/7/9 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Purpose of review: Pathological roles of macrophage migration inhibitory factor (MIF) have recently been demonstrated in spondyloarthritis (SpA) preclinical models, identifying MIF as a new treatment target for SpA. However, the specific contribution of MIF and therapeutic potential of MIF-targeted therapies to various tissue types affected by SpA are not well delineated.

Recent findings: MIF and its cognate receptor CD74 are extensively involved in the pathogenesis of SpA including inflammation in the spine, joint, eyes, skin, and gut. The majority of the current evidence has consistently shown that MIF drives the inflammation in these distinct anatomical sites. In preclinical models, genetic deletion or blockade of MIF reduces the severity of inflammation. Although MIF is generally an upstream cytokine which regulates downstream effector cytokines, MIF also intensifies type 3 immunity by promoting helper T 17 (Th17) plasticity. MIF- or CD74-targeted therapies have also reported to be well tolerated in clinical trials for other diseases. Recent findings suggest that MIF-CD74 axis is a new therapeutic target for SpA to improve various clinical features. Clinical trials for MIF- or CD74-targeted therapies for SpA patients are warranted.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

深入了解MIF在脊椎关节炎中的作用。

综述目的:巨噬细胞迁移抑制因子(macrophage migration inhibitory factor, MIF)在脊椎关节炎(spondyloarthritis, SpA)临床前模型中的病理作用已被证实，MIF是治疗SpA的新靶点。然而，MIF的具体贡献和MIF靶向治疗对SpA影响的各种组织类型的治疗潜力尚未得到很好的描述。最近发现:MIF及其同源受体CD74广泛参与SpA的发病机制，包括脊柱、关节、眼睛、皮肤和肠道的炎症。目前的大多数证据一致表明，MIF驱动这些不同解剖部位的炎症。在临床前模型中，基因缺失或阻断MIF可降低炎症的严重程度。虽然MIF通常是调节下游效应细胞因子的上游细胞因子，但MIF也通过促进辅助性t17 (Th17)的可塑性来增强3型免疫。据报道，MIF-或cd74靶向治疗在其他疾病的临床试验中也具有良好的耐受性。最近的研究表明，MIF-CD74轴是一个新的治疗靶点，可以改善SpA的各种临床特征。针对SpA患者的MIF或cd74靶向治疗的临床试验是有必要的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Rheumatology Reports RHEUMATOLOGY-

CiteScore

11.20

自引率

0.00%

发文量

期刊介绍： This journal aims to review the most important, recently published research in the field of rheumatology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care and prevention of rheumatologic conditions. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas such as the many forms of arthritis, osteoporosis and metabolic bone disease, and systemic lupus erythematosus. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also occasionally provided.